Moleculin Biotech is trading 5.88% up at $0.65 after rising from a $0.61 close on August 18, 2026; no new company-specific announcement clearly explains the August 19 pre-market move.
- The August 14 second-quarter report highlighted continued MIRACLE trial progress and funding expected to support operations into the first quarter of 2027.
- The broader market is essentially flat before the August 19 FOMC Minutes, so macro conditions do not clearly explain the isolated move.